JP Patent

JP7223701B2 — ４－ピリミジンスルファミド誘導体の、エンドセリン関連疾患治療用の有効成分との合剤

Assigned to Idorsia Pharmaceuticals Ltd · Expires 2023-02-16 · 3y expired

What this patent protects

Patent listed against Tryvio.

Drugs covered by this patent

Patent Metadata

Patent number
JP7223701B2
Jurisdiction
JP
Classification
—
Expires
2023-02-16
Drug substance claim
No
Drug product claim
No
Assignee
Idorsia Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.